Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:46:36.638Z.
Calculation as of: 2026-10-06T14:46:36.638Z.
Quote observation: 2026-10-06T14:45:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
PEG RATIO
N/A
enGene Holdings Inc.
Market Cap
$121.22M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| enGene Holdings Inc. (ENGN) | $121.22M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.72M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | N/A |
| Cibus, Inc. (CBUS)vs › | $123.66M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.86M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.57M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.99M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.65M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
